Bristol-Myers Squibb shares drop more than 3% after bearish technicals and ongoing workforce reductions
Bristol-Myers Squibb Company (BMY) dropped 3.33% today after multiple institutional investors reduced their holdings, and ongoing cost-cutting actions remained in focus. The decline is supported by bearish near-term technicals, with BMY trading below its 20-day and 50-day moving averages.
Highlights
- Institutional investors trimmed positions in Bristol-Myers Squibb during the third quarter and the company terminated a Cellares CAR-T partnership.
- Bristol-Myers Squibb confirmed a quarterly dividend of $0.63 per share, maintaining a 4% yield with a 55.88% payout ratio as revenue rose 6.9% year-over-year.
- Shares of Bristol-Myers Squibb trade below short-term averages under sustained downside pressure, with an expected five-day range of $59.05 to $62.64 and over 80% probability of consolidation or move higher.
Investor exits counter rising revenue amid persistent selling pressure
During the third quarter, several institutional investors reduced their positions in Bristol-Myers Squibb, including Machina Capital S.A.S., Patrick Mauro Investment Advisor INC., and Cullen Capital Management LLC, while White Pine Capital LLC started a new position. The company confirmed a quarterly dividend of $0.63 per share, maintaining a 4% yield and a payout ratio of about 55.88%. Revenue rose 6.9% year-over-year, with analysts expecting full-year EPS near 6.46. Workforce reductions and the termination of the Cellares CAR-T cell therapy partnership have also been disclosed, though price action has remained under broader selling pressure.
Short-term bearish trend persists as mixed technical signals emerge
Bristol-Myers Squibb is trading below its 20-day and 50-day moving averages ($62.30 and $61.83), but remains above the 200-day moving average ($60.38), indicating near-term bearish pressure with longer-term support holding. The Ichimoku Kijun at $60.85 acts as immediate support, with the next key floor at $60.73 and resistance at $61.35. Momentum indicators are mixed; MACD and Awesome Oscillator signal a bullish bias, ADX reads as neutral. Both the RSI and Stochastic RSI are neutral, while the CCI is in the overbought zone, suggesting caution for a potential downside correction. Bull/Bear Power is positive, indicating intraday buying momentum, even though the stock experienced a sharp pullback with price near session lows and volatility at 2.22%. This position reflects continued downside pressure despite some underlying bullish momentum signals.
Earlier, analysts noted that Bristol Myers Squibb raised its full-year revenue forecast amid strong demand for newer medicines, even as it faced acquisition-related charges and continued to see shifts in its product mix. The current technical setup, combined with the impact of institutional repositioning and cost-cutting measures, adds a layer of caution, making the $60.73 support and $61.35 resistance key levels to watch for a potential directional move in the coming sessions.